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Abstract The objective of this study was to investigate
the prevalence of gastric mucosal injury induced by non-
steroidal anti-inflammatory drugs (NSAIDs) in patients
with rheumatoid arthritis (RA). Upper gastrointestinal
endoscopy was performed on 100 RA patients treated with
NSAIDs. Patient factors potentially contributing to the
development of NSAID-induced gastric mucosal injury
were identified by logistic regression analysis; gastric
mucosal injury and ulcers were used as objective variables.
Gastric mucosal injury was detected in 62 of 100 patients,
and eight of these patients had ulcers. Previous history of
ulcers, lifestyle, NSAID dosage, and body mass index were
associated with the development of gastric mucosal injury,
and the use of diclofenac and steroid dose were associated
with the development of ulcers. Disease-modifying anti-
rheumatic drugs (DMARDs) did not appear to influence the
risk of NSAID-induced gastric mucosal injury. RA patients
treated for long periods with NSAIDs for RA symptoms
should be controlled with DMARDs, without consideration
of increased doses of steroids, in terms of risk for NSAID-
induced gastric mucosal injury. Simultaneously, concomi-
tant use of histamine-2 receptor antagonists (H2RA) such
as famotidine should be considered.
Keywords NSAID  Steroid  Rheumatoid arthritis 
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Introduction
In drug therapy for rheumatoid arthritis (RA), nonsteroidal
anti-inflammatory drugs (NSAIDs) are commonly used as
symptomatic treatment for swelling and pain of the joints
from very early stages of the disease [1]. Whereas NSAIDs
exert immediate anti-inflammatory and analgesic effects by
inhibiting cyclooxygenase (COX) activity and thereby
suppressing prostaglandin (PG) production [2, 3], they are
also known to cause gastric mucosal injury as an adverse
effect [4]. NSAID-induced gastric mucosal injury is often
associated with no subjective symptoms due to the anal-
gesic effect of the drugs [5–7], and the damage often
becomes apparent only with abrupt hematemesis. Further-
more, other drugs that may exacerbate NSAID-induced
gastric mucosal injury, such as steroids and disease-modi-
fying antirheumatic drugs (DMARDs), are commonly used
to treat RA. RA patients may thus be expected to be at a
higher risk of NSAID-induced gastric mucosal injury than
patients with other diseases. In Japan, however, the last
epidemiological study of NSAID-induced gastric mucosal
injury in RA patients was conducted by Shiokawa et al. [8]
in 1991, and no such study has been conducted since.
The famotidine or rebamipide in comparison by
endoscopy (FORCE) study examined the prevalence of
gastric mucosal injury based on upper gastrointestinal
endoscopic findings in 261 patients receiving long-term
NSAID therapy and evaluated the efficacy of famotidine
and rebamipide for the treatment of such gastric mucosal
injury. The study has already been published in detail
elsewhere [9, 10]. For this report, we selected 100 RA
patients from the FORCE study population and examined
the prevalence of gastric mucosal injury in RA patients
receiving long-term NSAID therapy to identify patient
factors contributing to the development of such mucosal
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injury and compare the effects of famotidine and reb-
amipide in the treatment of NSAID-induced gastric
mucosal injury of RA patients.
Materials and methods
A multicenter study was conducted from May 2004 to July
2005 by gastroenterologists and orthopedists from the Nara
Medical University and its four affiliated institutions,
namely, Nara Prefectural Nara Hospital, Nara Prefectural
Gojo Hospital, Kokuho Central Hospital, and Nishi Nara
Chuo Hospital. The protocol was approved by the institu-
tional review boards of all participating institutions. The
study was conducted in compliance with the standards of
Good Clinical Practice, and written informed consent was
obtained from each of the study participants.
Materials
Subjects were RA outpatients ranging in age from 20 and
74 years who were under oral treatment with any NSAID
other than aspirin for at least the previous 4 weeks. Patients
receiving any histamine-2 receptor antagonists (H2RA),
proton pump inhibitors (PPIs), muscarinic receptor antag-
onists, or PGs within 4 weeks prior to the endoscopy
were excluded from the study. In addition, patients with
any changes in the treatment regimen with NSAIDs or
DMARDs within 4 weeks prior to the endoscopy, includ-
ing any changes in the dosage or administration schedule,
were also excluded. Also, patients with any changes in the
treatment regimen with adrenocortical hormones, exclud-
ing external application, within 14 days prior to the
endoscopy were excluded.
Methods
After a complete medical history was obtained from the
patients who had provided their consent for participation in
the study, a urinary anti-Helicobacter pylori (H. pylori)
antibody test [enzyme-linked immunosorbent assay
(ELISA)] was conducted, followed by upper gastrointesti-
nal endoscopy, regardless of whether symptoms were
present. The modified Lanza score (hereafter referred to as
the Lanza score) [11], determined based on a scoring sys-
tem reported by Lanza [12], was estimated for evaluation
of endoscopic findings. In this scoring system, the severity
of gastric mucosal injury as viewed by endoscopy is graded
on a scale of 0–5, as follows: absence of gastric mucosal
injury is assigned a score of 0, with the score increasing
with severity of mucosal injury to a maximum score of 5,
which represents the presence of mucosal ulcers.
Investigations and statistical analyses
The prevalence of gastric mucosal injury was estimated
based on the Lanza scores as determined by endoscopy. In
addition, patient factors potentially contributing to the
development of gastric mucosal injury were identified by
logistic regression analysis. Gastric mucosal injury (Lanza
score 0 or 1–5) and ulcers (Lanza score 0–4 or 5) were used
as objective variables. Patient background factors, includ-
ing gender, age, H. pylori infection, type of NSAIDs, and
subjective symptoms, were used as explanatory variables.
In logistic regression, the odds ratio (OR) and 95% confi-
dence interval (95% CI) were calculated in a stepwise
manner for selected explanatory variables according to the
inclusion criteria for the explanatory variable as p \ 0.1.
The p value was calculated using the Wald test, and
p \ 0.05 was considered statistically significant.
Scores were assigned to the DMARDs, one of the
explanatory variables, based on the intensity of their anti-
rheumatic effects as specified in the Treatment Manual for
Rheumatoid Arthritis [13] and were used as continuous
variables (Table 1). When multiple drugs were used, the
scores for each drug were added together. For steroids, the
doses listed in Table 2 were used as continuous variables.
Patient background factors contributing to the develop-
ment of gastric mucosal injury were analyzed by primarily
examining the prevalence of gastric mucosal injury in
relation to patient background factors that would be
expected to play a particularly important role in the
development of gastric mucosal injury in RA patients, such
as NSAID dose, steroid dose, and concomitant DMARD use.
Patients with a Lanza score of 1–4 (gastric hemorrhage
or erosion) were considered eligible for treatment, whereas
those with Lanza scores of 0 (no gastric mucosal lesion) or
5 (gastric ulcer) were excluded from the treatment group.
Eligible patients were randomly assigned to receive either
Table 1 Details of concomitantly used drugs [disease-modifying
antirheumatic drugs (DMARDs)]
Drug Antirheumatic effect Scorea No. of patients
Methotrexate High 3 44
Bucillamine Moderate 2 53
Salazosulfapyridine Moderate 2 6
Actarit Low 1 13
Auranofin Low 1 9
Mizoribine Low 1 2
None 0 9
a The DMARDs were assigned scores based on the intensity of their
antirheumatic effects as specified in the Treatment Manual for
Rheumatoid Arthritis: Manual for Diagnosis and Treatment Guide-
lines based on evidence-based medicine issued by the Japan Rheu-
matism Foundation. When multiple drugs were used, the scores for
each drug were added together
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famotidine 20 mg/day (group F) or rebamipide 300 mg/day
(group R). Changes in the Lanza scores and the rate of
complete cure (percentage of patients showing reversal to a
Lanza score of 0 after treatment with either drug) after
4 weeks of treatment with either drug under continuation
of NSAID therapy were examined in each group. To
objectively evaluate the results, again, a third party una-
ware of which drug was administered or when endoscopy
would be performed examined the Lanza scores before and
after the treatment. Within-group and between-group
comparisons of changes in the Lanza scores estimated
before and after treatment with the drugs under investiga-
tion were analyzed by the Wilcoxon signed rank test and
Wilcoxon rank test, respectively, and the rates of complete
cure were compared by Fisher’s exact probability test, with
the significance level set at p \ 0.05, respectively.
Results
Patient background factors
The background factors of the 100 RA patients examined
in this study are shown in Table 3. The mean age of
patients was 57.7 years; female patients accounted for 80%
of the study population. Only 35.0% of patients reported
subjective abdominal symptoms. A previous history of
ulcers was reported by 10.0% of patients, of which 57.0%
were positive for antibody to H. pylori. In regard to the
NSAID used for the treatment, loxoprofen was the most
commonly used NSAID (33 patients), followed by a sus-
tained-release preparation of diclofenac. DMARDs were
used concomitantly in 91 patients and steroids in 47
patients. Ninety-eight patients were prophylactically
administered mucoprotective drugs.
Details of gastric mucosal injury
The prevalence and severity of gastric mucosal injury in
the patients at the first endoscopy are shown in Fig. 1.
Gastric mucosal injury was found in 62 patients (62.0%),
of which eight patients (8.0%) had ulcers. Analysis by the
Lanza score showed that grade 3 was the most frequently
observed, with a mean score of 2.8 in the patients with
mucosal injury.
In the FORCE study, the prevalence of gastric mucosal
injury and ulcers in the 161 patients with underlying dis-
eases other than RA, such as osteoarthritis and lumbar
spinal canal stenosis, were 63.4% and 11.8%, respectively,
which were similar to the incidence in RA patients.
Results of logistic regression analysis
The following are the results of the logistic regression
analysis where the criterion variables were gastric mucosal
lesions and ulcers, and the factors in the medical history
shown in Table 3, were candidates for explanatory variables.
The analysis identified a previous history of ulcers, lifestyle,
NSAIDs dose, and body mass index (BMI) as patient factors
that were significantly associated with the development of
gastric mucosal injury. The OR (95% CI, p value) was 7.53
(1.29–44.06, p = 0.025) for a previous history of ulcers,
4.00 (1.60–10.03, p = 0.003) for worsening of the lifestyle
from good or fair to poor, 3.15 (1.35–7.36, p = 0.008) for an
increase in NSAIDs dose from half dose or standard dose
to double dose or multiple drugs, and 1.30 (1.08–1.58,
p = 0.006) for every one increase in BMI (Fig. 2).
The use of diclofenac and steroid dose were identified as
patient factors significantly associated with the develop-
ment of ulcers. The OR (95% CI) was 14.15 (2.15–93.32,
p = 0.006) for the use of diclofenac instead of other
NSAIDs and 1.56 (1.15–2.12, p = 0.005) for an increase in
steroid dose by 1 mg, suggesting that the use of diclofenac
is a major risk factor for the development of ulcers (Fig. 3).
Prevalence of gastric mucosal injury in relation
to patient background factors
The prevalence of gastric mucosal injury by NSAID dose,
NSAID type, steroid dose, and concomitant DMARD use
were as follows: In relation to NSAIDs, prevalence was
57.6% with half to standard doses, 57.1% with the standard
dose, and 92.3% with twice the standard dose or the use of
multiple drugs, including aspirin; a high prevalence of gas-
tric mucosal injury was observed in patients administered
double the standard dose or multiple NSAIDs, including
aspirin (Fig. 4). Analysis by NSAID type showed gastric
mucosal injury in 90.0% of patients receiving diclofenac and
60.6% of those receiving loxoprofen. Gastric mucosal injury
was also found in 71.4% of patients receiving meloxicam and
etodolac, which have high selectivity for COX-2, with no
difference in the incidence compared with conventional
NSAIDs.
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Whereas no substantial differences were found in the
prevalence of gastric mucosal injury analyzed according to
steroid dose, the prevalence of ulcers was 1.9% in patients
who did not receive steroids, 10.3% in those treated with
steroids at 5 mg or less, and 37.5% in those treated with
steroids at 7.5 mg or more, with a particularly high prev-
alence in those administered high doses (C7.5 mg) of
steroids. Exclusion from the analysis of patients treated
with diclofenac, which was considered as the strongest risk
factor for the development of ulcers based on the results of
the logistic regression analysis, did not affect results on the
prevalence of ulcers, which was 2.0% in patients who did
not receive steroids, 3.0% in those treated with steroids at
5 mg or less, and 28.6% in those treated with steroids at
7.5 mg or more (Fig. 5).
Analysis of the prevalence of gastric mucosal injury in
relation to the concomitant use of DMARDs, which were
assigned scores according to the potency of their anti-
rheumatic effects, showed that gastric mucosal injury and
ulcers and the mean Lanza scores were higher in patients
receiving DMARDs assigned higher scores. However, the
Fig. 1 Detailed findings of gastric mucosal injury at the first
endoscopy
Table 3 Patient background factors (n = 100 patients)


























Preferential COX-2 inhibitor c 14 14.0
Diclofenac 10 10.0
Diclofenac SR 16 16.0
Others 38 38.0
NSAIDs administration
1–3 months 7 7.0
[3 months 93 93.0
Dosage of NSAIDsa
Below usual dose 28 28.0
Usual dose 59 59.0
Double or combinationd 13 13.0











\5 mg 39 39.0
Table 3 continued
Factors in medical history Number Percent
\7.5 mg 8 8.0
The mean and range of all patients’ ages are 57.7 years and 29.0–
74.0 years, respectively; the mean and range of all patients’ body
mass index (kg/m2) are 22.0 and 14.7–30.0, respectively
NSAIDs nonsteroidal antiinflammatory drugs, DMARDs disease-
modifying antirheumatic drugs, COX cyclooxygenase
a Factors used as continuous variables in multilogistic regression
analysis (the rest are discrete variables)
b Including duplication due to combination
c Meloxicam (n = 13) ? Etodolac (n = 1)
d Combination between NSAIDs, including aspirin
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trend became less when patients treated with diclofenac,
the strongest risk factor for ulcers, was excluded from the
analysis (Fig. 6).
The prevalence of gastric mucosal injury and ulcers
analyzed in relation to other patient background factors
were as follows: 62.3% in patients aged B64 years and
60.9% in those aged C65 years, 62.8% in those negative
and 61.4% in those positive for H. pylori infection, 55.4%
in those without subjective symptoms and 74.3% in those
with subjective symptoms, 57.1% in those administered
NSAIDs for 1–3 months and 62.4% in those administered
NSAIDs for C3 months, and 53.8% in those treated with
rebamipide and 63.8% in those treated with teprenone used
as a mucoprotective drug.
Evaluation of therapeutic effect
Of the 54 patients with hemorrhage or erosion (Lanza score
1–4), one was not randomized because of the need for
treatment for esophageal cancer. Of the 53 randomized
patients, one refused to undergo the second endoscopy, and
five patients were excluded from the analysis because of a
change in NSAID dose, leaving 47 patients (21 in group F
and 26 in group R) whose endoscopic findings after com-
pletion of treatment were available for analysis. The
characteristics of each group are shown in the Table 4. No
significant differences were found in the patient back-
ground factors between the two groups, except for the
higher mean age of group R than group F. The changes in
Lanza scores in both groups are shown in Fig. 7. The mean
Lanza score in group F decreased significantly from 2.1 to
1.1 (p = 0.014), whereas the score in group R increased,
Fig. 2 Patient factors associated with the development of gastric
mucosal injury. Asterisk including concomitant aspirin
Fig. 3 Patient factors associated with the development of ulcers
Fig. 4 Presence/absence of gastric mucosal injury in relation to
nonsteroidal anti-inflammatory drugs (NSAIDs) dose. Asterisk
including concomitant aspirin
Fig. 5 Presence/absence of gastric mucosal injury in relation to the
steroid dose
Fig. 6 Presence/absence of gastric mucosal injury in relation to
concomitant disease-modifying antirheumatic drug (DMARD) use
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although not statistically significantly (p = 0.298), from
1.8 to 2.2. There was a significant difference in the change
in the Lanza scores between groups (p = 0.003). The rate
of complete cure was 57.1% (12/21 patients) in group F,
whereas it was as low as 19.2% (5/26 patients) in group R
(p = 0.014). In regard to adverse drug reactions, mild back
pain was reported in one patient in group F, whereas all the
other reported events were mild abnormalities in laboratory
test values, with no report of any serious adverse drug
reactions.
Discussion
The incidence of gastrointestinal lesions in patients
receiving long-term NSAID therapy was reported by the
Japan Rheumatism Foundation in 1991 [8] to be 62.2%,
which is similar to the incidence determined in our study.
An incidence of gastric mucosal injury associated with
NSAID use of [60% was unexpected with the current
availability of NSAIDs that are highly selective for COX-2,
such as meloxicam and etodolac, which are considered to
be less likely to cause gastric mucosal injury. Meanwhile,
celecoxib—a COX-2-selective inhibitor demonstrated in
foreign clinical studies to be less likely to cause gastroin-
testinal damage than conventional NSAIDs—has also
become available in Japan. Celecoxib, which was not
included in our study, is shown to be less likely to cause
gastrointestinal damage in clinical trials of celecoxib in
Japan, and it is therefore necessary to evaluate the inci-
dence of gastric mucosal injury associated with the use
of this drug by accumulating clinical data in Japanese
patients. Similar to the results obtained in previous studies,
our study also identified a previous history of ulcers and a
high NSAID dose as significant risk factors for gastric
mucosal injury associated with long-term NSAID therapy
and steroid dose as a significant risk factor for the devel-
opment of ulcers associated with NSAID use [14, 15].
In our study, diclofenac, which is known to have potent
anti-inflammatory effects, was selected as the drug associated
with the greatest risk for the development of mucosal ulcers.
As the drug has also been reported to be associated with a
higher risk of upper gastrointestinal bleeding than other
NSAIDs [16], diclofenac must be used with care.
Analysis of prevalence of gastric mucosal injury by
patient background factors revealed higher incidence of
injury associated with higher doses of NSAIDs; prevalence
was especially high in those administered double the usual
doses or multiple NSAIDs, including aspirin. Studies from
abroad have also reported that the relative risk of devel-
oping NSAID-induced peptic ulcers is particularly high in
patients administered high doses of NSAIDs [17].
Ulcers caused by steroid treatment alone were first
reported by Sandweiss in 1954 [18]. Since then, both
positive [19, 20] and negative [21, 22] relationships
between steroids and peptic ulcers have been reported.
Possible reasons for the controversy include ambiguous
definitions of steroid-induced ulcers; endoscopy not per-
formed in all patients; differences in the type, dose, and
duration of use of steroids; differences in concomitantly
used drugs; and underlying diseases. On the other hand, it
is almost universally agreed that concomitant NSAID use
with steroids increases the risk of ulcers [14, 15]. In this
study, ulcers were observed at a high frequency in patients
taking steroids at doses of 7.5 mg or higher; exclusion from
the analysis of patients administered diclofenac, which is
considered to pose the greatest risk for ulcers, did not affect
the result.
The efficacy of DMARDs has recently been recon-
firmed. These agents are administered from an early stage
after the diagnosis of RA [12], often concomitantly with








Age (Years) 55.19 ± 9.08 61.00 ± 8.14 0.026
Gender
Female 19 20 0.402
Anti-Helicobacter pylori antibody
Positive 9 17 0.212
Peptic ulcer history
Yes 19 24 0.763
Smoking habit
Yes 20 22 0.485
DMARDs
Yes 21 24 0.567
Bisphosphonate
Yes 4 1 0.288
Steroids
Yes 6 12 0.352
DMARDs disease-modifying antirheumatic drugs
Fig. 7 Changes in the Lanza scores following treatment with
famotidine/rebamipide. a Wilcoxon’s signed rank test. b Wilcoxon’s
rank test
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NSAIDs even before the definitive diagnosis. Although
some DMARDs are associated with a high risk of gastro-
intestinal adverse effects, gastrointestinal mucosal damage
induced by DMARDs has not been reported as frequently
as that induced by NSAIDs or steroids. It is also unclear
whether the concomitant use of DMARDs with NSAIDs
might increase the risk of gastric mucosal injury. In this
study, the prevalence and severity of gastric mucosal
injury, including ulcers, was higher in patients adminis-
tered DMARDs with more potent antirheumatic effects;
however, the trend became less significant when patients
treated with diclofenac, the NSAID associated with the
greatest risk of gastric mucosal ulcers, were excluded. The
results might suggest that RA patients administered
DMARDs with highly potent antirheumatic effects tend to
have severe RA and, therefore, also tend to be administered
NSAIDs with potent anti-inflammatory and analgesic
effects, consequently being at a higher risk of gastric
mucosal injury. In the final analysis, concomitant DMARD
administration is considered to have little effect on
NSAID-induced gastric mucosal injury.
In Japan, mucoprotective drugs are commonly used to
treat gastric mucosal injury during NSAID therapy. How-
ever, in this study, rebamipide had no therapeutic effect on
NSAID-induced gastric mucosal injury in RA patients,
whereas famotidine (20 mg/day), which is covered by
health insurance, was an effective drug. These results
indicate the involvement of gastric acid [23] and the
inhibitory effect of NSAIDs on PG biosynthesis [24]—
which has been considered to be the cause of NSAID-
induced gastric mucosal injury—in NSAID-induced gastric
mucosal injury. The efficacy of acid suppressors against
NSAID-induced gastric mucosal injury has actually been
demonstrated [25–27], lending support to the proposed
mechanism above of the effects of these NSAIDs.
In Japan, the use of PPIs, PG preparations, and high
doses of H2RA is recommended in the Treatment Manual
for Rheumatoid Arthritis [13] and the Treatment Guidelines
for Gastric Ulcer, Ver. 2., for the treatment/prevention of
NSAID-induced ulcers [28], and PPI therapy is restricted in
Japan. In our study, evaluation included the therapeutic
effect of famotidine on preulcer lesions of the gastric
mucosa, such as erosions and bleeding, which may explain
why the drug exhibited therapeutic effects at a lower dose
than that specified in the guidelines (80 mg). In addition,
most of the evidence to date has been adopted from
guidelines developed in the United States and Europe.
Thus, the lower acid-secretory capacity of the Japanese
people compared with that of people from the United States
or Europe [29–31] and the consequently lower doses of
NSAIDs approved in Japan (one half to one third of those
approved in the United states and Europe) may also explain
the phenomenon. For patients at high risk because of a
previous history of upper gastrointestinal bleeding, how-
ever, the use of COX-2-selective inhibitors that are
expected to rarely cause gastrointestinal damage, such as
celecoxib, may be recommended concomitantly with a PPI.
In this study, we examined RA patients selected from
the population of the FORCE study but found that the risk
factors and prevalence of gastric mucosal injury, and also
the efficacy of famotidine (20 mg/day), were similar to the
respective results obtained for the entire FORCE study
population [9, 10]. Our results suggest that treatment with
famotidine (20 mg/day) is effective even in RA patients,
who are often administered steroids or DMARDs con-
comitantly with NSAIDs. As mild gastric mucosal injury,
such as erosion, is at a high risk of developing into ulcers
even after long-term follow-up [32], there will be an
increasing need to manage patients receiving long-term
NSAID therapy to prevent gastric mucosal damage.
Conclusion
The prevalence of NSAID-induced gastric mucosal injury
in RA patients in this study was similar to that reported by
the Japan Rheumatism Foundation in 1991 [5], suggesting
that the incidence of gastric mucosal injury remains high
even after the relatively recent introduction of NSAIDs
considered to be highly selective for COX-2. Risk factors
for gastric mucosal injury in the patients were also similar
to those reported in previous studies, with higher doses of
NSAIDs being associated with a higher risk of gastric
mucosal injury and higher doses of steroids administered
concomitantly with NSAIDs being associated with a higher
risk of ulcers. On the other hand, concomitant use of
DMARDs did not appear to significantly influence the risk
of NSAID-induced gastric mucosal injury. The efficacy of
famotidine (20 mg/day) in the treatment of gastric mucosal
injury associated with NSAID use was also confirmed.
Acknowledgments This study was supported by Astellas Pharma
Inc., Tokyo, Japan.
Conflict of interest statement There are no competing interests.
References
1. American College of Rheumatology Subcommittee on Rheuma-
toid Arthritis Guidelines. Guidelines for the management of
rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46(2):
328–46.
2. Jack DB. One hundred years of aspirin. Lancet. 1997;350(9075):
437–9.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of
action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–5.
Mod Rheumatol (2009) 19:629–636 635
123
4. Douthwaite AH. Gastroscopic observation of the effect of aspirin
and certain other substances on the stomach. Lancet. 1938;2:
1222–5.
5. Shiokawa Y, Nobenaga T, Saitoh T, Asagi S, Ogawa A. Epide-
miological study on upper digestive injuries by non-steroidal anti-
inflammatory drugs (in Japanese). Off J Jpn Rheum Assoc.
1991;31:96–111.
6. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory
drugs and life threatening complications of peptic ulceration. Gut.
1987;28:527–32.
7. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF.
Gastrointestinal tract complications of nonsteroidal anti-inflam-
matory drug treatment in rheumatoid arthritis. A prospective
observational cohort study. Arch Intern Med. 1996;156:1530–6.
8. Shiokawa Y, Nobenaga T, Saitoh T, Asagi S, Ogawa A. Epidemi-
ological study on upper digestive injuries by non-steroidal anti-
inflammatory drugs (in Japanese). J Jpn Rheum Assoc. 1991;31(1):
96–111.
9. Yamao J, Kikuchi E, Matsumoto M, Nakayama M, Ann T,
Kojima H, et al. Assessing the efficacy of famotidine and reb-
amipide in the treatment of gastric mucosal lesions in patients
receiving long-term NSAID therapy (FORCE-famotidine or
rebamipide in comparison by endoscopy). J Gastroenterol.
2006;41:1178–85.
10. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date informa-
tion on gastric mucosal lesions from long-term NSAID therapy in
orthopedic outpatients: a study using logistic regression analysis.
J Orthop Sci. 2007;12(4):341–6.
11. Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku
Y, et al. Rebamipide protects against indomethacin-induced
gastric mucosal injury in healthy volunteers in a double-blind,
placebo-controlled study. Dig Dis Sci. 1998;43:83–9.
12. Lanza FL, Royer GL, Nelson RS, Chen TT, Seckman CE, Rack
MF. A comparative endoscopic evaluation of the damaging
effects of nonsteroidal anti-inflammatory agents on the gastric
and duodenal mucosa. Am J Gastroenterol. 1981;75:17–21.
13. Japan Rheumatism Association; Treatment Manual for Rheu-
matoid Arthritis (Revised Version of Diagnostic Manual and
EBM-based Treatment Guidelines) (in Japanese). Japan Rheu-
matism Foundation Information Center. 2004.
14. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity
of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:
1888–99.
15. Scheiman JM. Unmet needs in non-steroidal anti-inflammatory
drug-induced upper gastrointestinal diseases. Drugs. 2006;
66(suppl 1):15–21.
16. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida
Y, et al. Case-control study on the association of upper gastro-
intestinal bleeding and nonsteroidal anti-inflammatory drugs in
Japan. Eur J Clinic Pharmacol. 2006;62(9):765–72.
17. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated
peptic ulcer among users of aspirin and nonaspirin nonsteroidal
antiinflammatory drugs. Am J Epidemiol. 2004;159(1):23–31.
18. Sandweiss DJ. Effects of adrenocorticotropic hormone (ACTH)
and of cortisone on peptic ulcer. I. Clinical review. Gastroen-
terology. 1954;27(5):604–16.
19. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid
therapy and peptic ulcer. N Eng J Med. 1976;294(9):473–9.
20. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-
analysis of adverse events during steroid therapy. J Int Med.
1994;236:619–32.
21. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC.
Association of adrenocorticosteroid therapy and peptic-ulcer
disease. N Eng J Med. 1983;309:21–4.
22. Nielsen GL, Sørensen HT, Mellemkjoer L, Blot WJ, McLaughlin
JK, Tage-Jensen U, et al. Risk of hospitalization resulting from upper
gastrointestinal bleeding among patients taking corticosteroids: a
register-based cohort study. Am J Med. 2001;111(7):541–5.
23. Funatsu T, Chono K, Hirata T, Keto Y, Kimoto A, Sasamata M.
Mucosal acid causes gastric mucosal microcirculatory distur-
bance in nonsteroidal anti-inflammatory drug-treated rats. Eur J
Pharm.. 2007;554:53–9.
24. Robert A. Antisecretory, antiulcer, cytoprotective and diarrheo-
genic properties of prostaglandins. Adv Prostaglandin Throm-
boxane Res. 1976;2:507–20.
25. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell
J, et al. Famotidine for the prevention of gastric and duodenal
ulcers caused by non-steroidal antiinflammatory drugs. N Engl J
Med. 1996;334:1435–9.
26. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A,
Swannell AJ, et al. Omeprazole compared with misoprostol for
ulcers associated with nonsteroidal antiinflammatory drugs.
Omeprazole versus misoprostol for NSAID-induced Ulcer Man-
agement (OMNIUM) Study Group. N Engl J Med. 1998;338(11):
727–34.
27. Wu CS, Wang SH, Chen PC, Wu VCC. Does famotidine have
similar efficacy to misoprostol in the treatment of non-steroidal
anti-inflammatory drug-induced gastropathy? Int J Clin Pract.
1998;52(7):472–4.
28. Research team for the development of guidelines for evidence-
based gastric ulcer diagnosis, Guideline for Clinical Practice of
Gastric Ulcer Based on EBM, 2nd ed (in Japanese). Jiho. 2007.
29. Haruma K, Kamada T, Kawaguchi H, Okamoto S, Yoshihara M,
Sumii K, et al. Effect of age and Helicobacter pylori infection on
gastric acid secretion. J Gastroenterol Hepatol. 2000;15:277–83.
30. El-Omar EM, Penman ID, Ardill JES, Chittajallu RS, Howie C,
Mccoll KEL. Helicobacter pylori infection and abnormalities of
acid secretion in patients with duodenal ulcer disease. Gastro-
enterology. 1995;109:681–91.
31. Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison
of gastric acid secretion rates and serum pepsinogen I and II
concentrations in occidental and oriental duodenal ulcer patients.
Gastroenterology. 1988;95:630–5.
32. Toljamo KT, Niemela¨ SE, Karttunen TJ, Karvonen AL, Lehtola JK.
Clinical significance and outcome of gastric mucosal erosions: a
long-term follow-up study. Dig Dis Sci. 2006;51(3):543–7.
636 Mod Rheumatol (2009) 19:629–636
123
